POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy

The goal of this pilot clinical trial is to test the safety and effectiveness of genotype-guided clopidogrel monotherapy in patients presenting with Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) who have undergone successful Percutaneous Coronary Intervention (PCI). The main questions it aims to answer are: * Is genotype-guided clopidogrel monotherapy effective in reducing ischemic risk during the first six months following successful PCI? * Is genotype-guided clopidogrel monotherapy safe in terms of reducing bleeding risk during the first six months following successful PCI? Participants will be given genotype-guided clopidogrel monotherapy after their successful PCI procedure and will be monitored for any bleeding or ischemic complications over the next six months. Researchers will compare these results to the typical outcomes associated with traditional Dual antiplatelet therapy (DAPT) to see if genotype-guided clopidogrel monotherapy provides similar or improved protection from ischemic events, but with fewer bleeding complications.

NCT Number	NCT05926271
Lead Sponsor	St. Antonius Hospital
Conditions	Acute Coronary Syndrome, CYP2C19 Polymorphism
Enrollment	200 participants
Start Date	2023-07-15
Primary Completion	2026-06-15 (estimated)
Study Completion	2027-01-15 (estimated)
Updated on ClinicalTrials.gov	2024-12-03